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ABSTRACT
During respiratory-virus infection, excessive lymphocyte activation can cause pathology both in acute infection and in exacerbations of
chronic respiratory diseases. The costimulatorymolecule CD161 is expressed on lymphocyte subsets implicated in promoting re-
spiratory inflammation, including Th2, Th17, mucosally associated invariant T (MAIT) cells, and type 2 innate lymphoid cells.
We asked whether the CD161 ligand LLT1 could be expressed on respiratory epithelial cells following respiratory-virus infection
as a mechanism by which respiratory-virus infection could promote activation of proinflammatory lymphocytes. In response to
respiratory syncytial virus (RSV) infection, expression of LLT1 was upregulated in the BEAS-2B respiratory epithelial cell line
and primary human bronchial epithelial cells. Imaging studies revealed that LLT1 expression increased in both RSV-infected
and cocultured uninfected cells, suggesting that soluble factors produced during infection stimulate LLT1 expression. TLR3 and
TLR2/6 ligands led to a rapid increase in LLT1mRNA in respiratory epithelial cells, as did the proinflammatory cytokines type I
interferons, interleukin 1 (IL-1), and tumor necrosis factor alpha (TNF-), which are produced early in respiratory-virus in-
fection. Immunohistochemistry confirmed the increase in LLT1 protein on the epithelial cell surface, and live-cell confocal mi-
croscopy demonstrated accumulation of epithelial LLT1 at synapses formed with CD161 T lymphocytes. LLT1 expression by
the respiratory epithelium in response to respiratory-virus infection and inflammatory cytokines represents a novel link be-
tween innate immunity and lymphocyte activation. As a regulator of CD161 proinflammatory lymphocytes, LLT1 could be a
novel therapeutic target in inflammation caused by respiratory-virus infection.
IMPORTANCE
The immune response to respiratory-virus infection is essential for clearing the pathogen but, if excessive, can lead to tissue
damage and obstruction of the airways. How viral infection activates immune cells in the lungs is not fully understood. Here, we
show that LLT1 can be expressed in lung cells in response to infection. LLT1 triggers CD161, a receptor on inflammatory im-
mune cells. This mechanismmay promote activation of immune cells in the lungs in viral infection and could be a novel target
for therapies aimed at reducing lung inflammation.
In acute respiratory-virus infection, such as bronchiolitis causedby respiratory syncytial virus (RSV) infection, excessive lym-
phocyte activation can cause airway damage and occlusion, lead-
ing to loss of vital gaseous exchange. Furthermore, in chronic
diseases, such as asthma, inflammation is exacerbated by respira-
tory-virus infection, which promotes inflammation driven by
lymphocytes, particularly Th2 and Th17 cells (1–3). Understand-
ing how lymphocyte activity in the lungs is exacerbated by respi-
ratory-virus infection is therefore an important goal.
CD161 is a costimulatorymolecule found on proinflammatory
lymphocytes in the lungs and was first identified as a natural killer
(NK) cell receptor (4). Ligation of CD161 is inhibitory for NK cell
function but can promote T cell activation, proliferation, and cy-
tokine secretion (5–10). CD161 is expressed on a large proportion
of T cells at mucosal surfaces and on CXCR6 cells that traffic to
the lung (11–14). All Th17 lymphocytes express CD161 (11, 15–
17), and CD161 Th17 lymphocytes have been implicated in pro-
moting inflammation in RSV bronchiolitis, in allergic pulmonary
inflammation, and in asthma exacerbation (18–22). CD161 can
also be expressed onCD8T cells,T cells, NKT cells, and other
innate lymphoid cells that can promote inflammation in the air-
ways (13, 23). Interestingly, recent data suggest that cross-linking
of CD161 on mucosally associated invariant T (MAIT) cells,
which are highly CD161-expressing lymphocytes abundant at
mucosal surfaces, may modulate cytokine responses, but not cy-
totoxicity (24).
As CD161 is expressed on proinflammatory lymphocytes im-
plicated in driving respiratory inflammation, we wished to under-
stand how CD161 signaling is controlled in the lung. We asked
whether the CD161 ligand lectin-like transcript 1 (LLT1) was ex-
pressed on respiratory epithelial cells during respiratory-virus in-
fection (7, 25). LLT1 expression has been shown on peripheral-
blood-derived leukocytes, but its expression in the lung has not
been studied (8, 10). Here, we demonstrate that LLT1 expression
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is very rapidly upregulated on the surfaces of bronchial epithelial
cells in response to respiratory syncytial virus infection. Further-
more, proinflammatory cytokines released during respiratory in-
fection and stimulation of Toll-like receptors (TLR), including
TLR3, could also mediate LLT1 expression. Stimulation of LLT1
transcription leads to cell surface expression of LLT1 protein,
which clusters at the immunological synapse with CD161-ex-
pressing T lymphocytes. Thus, the CD161-LLT1 axis provides a
molecular link between respiratory-virus infection and regulation
of inflammatory lymphocytes in the lung and is a potential novel
therapeutic target in respiratory inflammation.
MATERIALS AND METHODS
Cell culture. The transformed human bronchial epithelial cell line
BEAS-2B (ATCC and LGC Standards, United Kingdom) was cultured in
RPMI 1640 medium supplemented with penicillin (100 U/ml), strepto-
mycin (100 g/ml), L-glutamine (0.8 mM) (culture medium), and 10%
heat-inactivated fetal calf serum (FCS) (all from PAA Laboratories). Pri-
mary isolates of normal human bronchial epithelial (NHBE) cells (Lonza)
were cultured usingClonetics BEBMmedium supplemented according to
themanufacturer’s instructions with bovine pituitary extract, insulin, hy-
drocortisone, gentamicin, amphotericin sulfate, transferrin, triiodothyro-
nine (T3), adrenaline, human epidermal growth factor, and retinoic acid.
Respiratory syncytial virus. Plaque-purified RSV strain A2 (ATCC)
was propagated inHep-2 cells. The viral titer was determined by infection
of Hep-2 cell monolayers for 1 h in serum-free medium, followed by
addition of culture medium containing 4% FCS. The titer was confirmed
on BEAS-2B monolayers under the conditions used for experiments. To
produce UV-inactivated virus, RSV stock was irradiated with UV light for
1min using a UVPCX-2000 UV cross-linker (Ultra-Violet Products Ltd.,
United Kingdom), and inactivation was confirmed by plaque assay.
Experimental stimulations and infections. Six-well culture plates
were coated in basement membrane matrix (Geltrex; Invitrogen) diluted
to 0.1 mg/ml in RPMI. BEAS-2B cells (0.5  106 per well) in culture
medium containing 2% FCSwere added and allowed to form an adherent
monolayer overnight. For viral infections, RSVwas added at amultiplicity
of infection (MOI) of 1.0 in serum-free RPMI medium for 2 h, and then,
an equal volume of 4% FCS culture medium was added to each well and
the plates were incubated for the desired length of time.
The following cytokines and TLR agonists were used for stimulations:
interleukin 1 (IL-1), IL-10, IL-17, IL-22, gamma interferon (IFN-),
transforming growth factor beta (TGF-), IFN-1, IFN-2, IFN-	,
IFN-, and IFN-
 (all from Peprotech, United Kingdom) and the TLR
agonists lipopolysaccharide (LPS), Pam3CSK4, HKLM, poly(I·C) high
molecular weight (HMW), poly(A·U), imiquimod, R848, CL075, single-
stranded RNA 40 (ssRNA40)/Lyovec, ssRNA41/Lyovec, and ODN 2006
(all from Invivogen). All stimulations were carried out in culturemedium
with 2% FCS.
RT-PCR analysis of LLT1 expression. Total RNA was extracted from
cells using TRIzoL reagent (Invitrogen), the quantity and purity were
determined using a NanoDrop 1000 spectrophotometer (Thermo-Fisher
Scientific Inc.), andRNAwas reverse-transcribed into cDNAusing a high-
capacity RNA-to-cDNA kit (Invitrogen) according to the manufacturer’s
instructions. A real-time reverse-transcription (RT)-PCR assay for LLT1
expression (clec2d gene) was performed using a TaqMan gene expression
assay (Applied Biosystems), and the transcript levels were expressed rela-
tive to a GAPDH (glyceraldehyde-3-phosphate dehydrogenase) endoge-
nous control (Applied Biosystems). The fold change in LLT1 expression
was calculated relative to unstimulated cells following normalization to
GAPDHexpression andwas expressed as 2CT (CT is the difference in
threshold cycles for the test gene and GAPDH; CT is the difference in
CT between stimulated cells and unstimulated controls).
Confocal imaging of RSV and LLT1. Overnight cultures of BEAS2B
cells, seeded at 4  105 cells per well in 6-well plates containing 16-mm
coverslips, were infected with RSV at an MOI of 1.0, and 20 h after infec-
tion, the cells were fixed with 4% paraformaldehyde, blocked with 3%
bovine serum albumin (BSA) in 0.2% Triton X-100, phosphate-buffered
saline (PBS) for 10 min, and coimmunostained with polyclonal anti-RSV
(1:200; Abcam) and anti-LLT1 (1:200; Novus Biologicals) for 1.5 h, fol-
lowed by secondary antibodies, anti-goat conjugated to Alexa Fluor 488
(AF488) (RSV) and anti-mouse AF568 (LLT1) (1:1,000; Invitrogen), for
45 min. Images were obtained on a Zeiss 5 Pascal confocal laser scanning
microscope using a 63/1.4 Plan-Apochromat oil lens (averaging 4
times). Images were acquired using Zeiss LSM Image Browser software
(4.2.0.121; Zeiss).
Immunohistochemistry. BEAS-2B cells were plated at a density of
2.5  104 per well in an 8-well chamber slide (Nunc, Rochester, NY),
stimulated as described above for 16 h, and fixed with 10% formalin. The
wells were blocked and then incubated with primary mouse LLT1 mono-
clonal antibody (MAb) (Novus Biologicals) or mouse IgG isotype control
at 4°C overnight, followed by rat anti-mouse IgG1 secondary antibody
(BD) and avidin-peroxidase (Sigma), and were developed with 3,3=-di-
aminobenzidine (DAB) substrate.
T cell transfection and flow cytometry. Jurkat leukemic T cells were
transiently transfected with CD161-enhanced yellow fluorescent protein
(EYFP) cloned into mammalian expression plasmid pcDNA3.1 (Invitro-
gen) by microporation (Digital Bio Technology, Seoul, South Korea),
with a single pulse of 30 ms at 1,380 V. After 24 h, the cells were stained
with LIVE-DEAD aqua stain (Invitrogen), followed by anti-CD161-allo-
phycocyanin (APC) (clone 191B8;Miltenyi Biotech). Flow cytometry was
performed on a BDFortessa instrument, and the data were analyzed using
FloJo software (Tree Star, Inc.), gating for live singlet cells before analysis
of CD161-EYFP and surface CD161 expression, detected with the CD161
antibody.
Live-cell confocal imaging. BEAS-2B cells were transfected with
LLT1-EYFP cloned into mammalian expression plasmid pcDNA3.1 (In-
vitrogen) using jetPrime reagent (Polyplus Transfection), following the
manufacturer’s protocol, and 0.5 g of plasmid.Stable transfectants were
selected using G418. LLT1-EYFP expressing BEAS-2B cells were seeded
onto treated chambered coverslides (Nunc, Rochester, NY) and left over-
night to adhere. Jurkat leukemic T cells were transfected with CD161-
mCherry as described above. The transfected Jurkat T cells were dropped
onto BEAS-2B cells, and the cellular interactions were imaged by reso-
nance scanning confocal microscopy using laser lines of 514 and 594 nm
and a 63 1.2-numerical-aperture (NA) water immersion objective (TCS
SP5 RS; Leica, Heidelberg, Germany). Live-cell images were developed at
37°C and 5%CO2, using 10% FCS-RPMI as the imagingmedium. Images
were developed using Leica Application Suite Advanced Fluorescence
(Leica, Heidelberg, Germany) software. Simultaneous imaging of differ-
ent fluorophores was done by sequential line scanning (TCS SP5).
Data analysis.The fold change in expression ofmRNAwas quantified
from RT-PCR data by the 2CT method using Microsoft Excel before
importing into GraphPad Prism (GraphPad Software, USA) for produc-
tion of graphs and statistical analysis. For multiple comparisons of test
samples to controls, one-way analysis of variance (ANOVA) was used
with Dunnett’s posttest, and P values of 0.05 were considered signifi-
cant.
RESULTS
LLT1 is expressed on respiratory epithelial cells in response to
RSV infection and is dependent on replicating virus. Respirato-
ry-virus infection can cause acute inflammation and exacerbation
of existing chronic inflammatory diseases, such as asthma. We
wished to determinewhether infection of the epitheliumwithRSV
could stimulate LLT1 expression. BEAS-2B cells were infected at
anMOI of 1.0 for 1 h in serum-freemedium, followed by addition
of medium containing serum for a further 5 h. We found basal
expression of LLT1 in the epithelial cells and that LLT1 expression
was further induced by infection.Wewanted to determine if rapid
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induction of LLT1 by RSV infection was due to the presence of
replicating virus or recognition of virus particles or due to another
component of the RSV stock, which is a relatively crude prepara-
tion made from infected Hep-2 cells. RSV was UV inactivated for
1 min, and inactivation was confirmed by plaque assay. LLT1 ex-
pression was greatly reduced following UV inactivation of RSV
(Fig. 1), which reveals that LLT1 expression is promoted by repli-
cating virus.
LLT1 is expressed in RSV-infected and cocultured unin-
fected cells. To further understand how LLT1 is regulated in re-
spiratory epithelial cells by respiratory-virus infection, cells were
infected and 20 h later were costained for RSV and for LLT1.
Confocal imaging revealed that LLT1 upregulation occurred in all
cells in infected cultures, in both infected anduninfected cells (Fig.
2), but not in wells where all cells were left uninfected. This sug-
gests that soluble factors present in the culture of infected cells
were able to mediate the upregulation of LLT1.
TheCD161 ligand LLT1 is rapidly expressed in bronchial ep-
ithelial cells in response to TLR ligands. RSV is detected by pat-
tern recognition receptors, including TLR3 and RIG-I. To deter-
mine whether TLR3 ligation can lead to expression of LLT1 and to
establish the optimal time point formeasurement of LLT1 expres-
sion, cells were stimulated with 10 g/ml poly(I·C) for 1, 2, 4, 8,
16, 24, 48, and 72 h, andmRNA expression was analyzed by quan-
titative RT-PCR. Expression was found to be induced rapidly and
peaked at 4 to 8 h, with an increase of about 35- to 40-fold relative
to unstimulated cells, and then declined to 10-fold by 72 h (Fig.
3a). A dose-response analysis of LLT1 expression at 4 h revealed
that bronchial epithelial cells were very sensitive to poly(I·C) stim-
ulation and responded over a range of concentrations, reaching
statistical significance at 1 and 10 g/ml (Fig. 3b).
As 4 h was discovered to be the peak of LLT1 expression,
BEAS-2B cells were stimulated with various TLR ligands, and ex-
pression was assessed by PCR after 4 h. Among the TLR ligands,
poly(I·C) (TLR3) revealed the greatest level of LLT1 expression;
however, FSL-1 (TLR2/6) also showed a high level of induction
(Fig. 4a). The TLR agonists LPS (TLR4), HKLM (TLR2),
Pam3CSK4 (TLR2), imiquimod (TLR7), R848 (TLR7/8), CL075
(TLR7/8), ssRNA40/Lyovec (TLR8), and ODN 2006 (TLR9) did
not significantly stimulate LLT1 expression at this time point at
the concentrations tested. Poly(I·C) can also signal through non-
TLR pathways, such as RIG-I. We tested the selective agonist
poly(A·U), which signals only through TLR3. This agonist was
able to upregulate LLT1, indicating that TLR3 signaling was in-
deed able to stimulate expression of LLT1 (Fig. 4a). Therefore,
LLT1 expression is a specific response to TLR3 ligation, a pathway
that is known to be stimulated during respiratory-virus infection
(26).
TheCD161 ligand LLT1 is rapidly expressed in bronchial ep-
ithelial cells stimulated in response to proinflammatory cyto-
kines. We then tested cytokines known to be produced during
respiratory-virus infections to determine whether they could in-
duce LLT1 expression. Different interferons were tested for the
ability to induce LLT1 expression. The type I interferon IFN-
induced a high level of LLT1 expression, as did IFN-	 (Fig. 4b).
FIG 1 LLT1 is expressed in response to respiratory syncytial virus infection.
BEAS-2B cells were infected with respiratory syncytial virus at an MOI of 1.0,
and expression of LLT1 was analyzed 6 h later by quantitative PCR. The data
are shown as fold induction above unstimulated control cells, normalized to
the GAPDH housekeeping gene. The data are means and standard deviations
(SD) of triplicate wells. ns, not significant; ***, P 0.001, and **, P 0.01 by
one-way ANOVA in comparison to unstimulated cells; the bar indicates com-
parison between groups.
FIG 2 LLT1 is expressed in cocultured RSV-infected and uninfected respiratory epithelial cells. BEAS2B cells were infected with RSV at anMOI of 1.0. After 20
h, the cells were stained with anti-RSV, followed by an AF488-conjugated secondary antibody (green) to identify RSV-infected cells and anti-LLT1 followed by
an AF568-conjugated secondary antibody to stain for LLT1 protein (red). Representative images show that both RSV-infected and cocultured uninfected cells
upregulated LLT1 (top row) compared to uninfected cultures (bottom row). Cell outlines are drawn in white in single-color fluorescent images, and uninfected
cells are indicated with arrows in the top row.
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IL-1 (10 ng/ml) and tumor necrosis factor alpha (TNF-	) (10
ng/ml) also induced rapid upregulation of LLT1 transcript in the
epithelial cells (Fig. 4c). Other cytokines tested that did not induce
a significant change in LLT1 expression at 4 h were IL-4 (10 ng/
ml), IL-6 (100 ng/ml), IL-8 (500 ng/ml), IL-33 (50 ng/ml), TGF-
(10 ng/ml), IL-10 (10 ng/ml), IL-17 (10 ng/ml), IL-22 (10 ng/ml),
IFN-1 (100 ng/ml), IFN-2 (100 ng/ml), IFN-
 (1,000 U/ml),
and IFN- (500 U/ml) (Fig. 4c).
We thenwished to confirm that primary human epithelial cells
could respond to TLR and cytokine stimuli by upregulating ex-
pression of LLT1 in the same way as the BEAS-2B cell line. Cul-
tured normal human bronchial epithelial cells also rapidly ex-
FIG 3 LLT1 expression is rapidly induced on bronchial epithelial cells by poly(I·C). (a) BEAS-2B monolayers were stimulated with 10-g/ml poly(I·C), and
LLT1 gene expression was determined by quantitative PCR at time points up to 72 h. (b) Dose-response curve of LLT1 expression in BEAS-2B cells in response
to poly(I·C) stimulation for 4 h. The data are shown as fold induction above unstimulated control wells, normalized to the GAPDHhousekeeping gene. The data
are means and SD of triplicate wells. *, P 0.05; **, P 0.01; ***, P 0.001 by one-way ANOVA. Conc., concentration.
FIG 4 LLT1 is induced by TLR ligands and cytokines. (a to c) BEAS-2B cells were stimulated with TLR ligands (a); type I, type II, and type III interferons (b); or
cytokines (c) for 4 h, and the fold induction of LLT1 expression was determined by quantitative PCR. (d) Expression of LLT1 by cultures of primary bronchial
epithelial cells from a single donor stimulated for 4 h. The data are shown as fold induction above unstimulated control wells, normalized to the GAPDH
housekeeping gene. The data are means and SD of triplicate wells. **, P 0.01, and ***, P 0.001 by one-way ANOVA.
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pressed LLT1 in response to the cytokines IL-1, TNF-	, and
IFN- and in response to poly(I·C) (Fig. 4d).
Our data demonstrate that respiratory epithelial cells upregu-
late expression of the CD161 ligand LLT1 following detection of
viral infection via the pattern recognition receptor TLR3 and fol-
lowing stimulation by the proinflammatory cytokines TNF-	, IL-
1, and type I IFNs,which are released early following respiratory-
virus infection.
LLT1 surface expression on respiratory epithelial cells. LLT1
is encoded by one of the alternatively spliced transcripts of the
Clec2d gene located in the natural killer gene complex (27). In
order to establish whether the increases in gene expression in-
duced by inflammatory stimuli lead to LLT1 protein on the epi-
thelial cell surface, immunohistochemistry was performed under
nonpermeabilizing conditions on BEAS-2Bmonolayers after 16 h
of stimulation. There was some expression of LLT1 in epithelial
cells in the absence of stimulation (visualized as brown DAB sub-
strate precipitate) and significant upregulation of expression in
cell monolayers stimulated with cytokines or poly(I·C) (Fig. 5).
Thus, the changes we observed in LLT1 gene expression led to
increased LLT1 protein on the cell surface.
LLT1 clusters at the immune synapse between respiratory
epithelial cells and CD161 T cells. We wished to determine
whether LLT1 expressed on epithelial cells could indeed interact
with lymphocytes expressingCD161 and to understand the nature
of the interaction. We utilized the Jurkat T cell line and used a
CD161 antibody to confirm that these T cells do not normally
express CD161 on the cell surface but do so when transiently
transfected with a CD161-EYFP construct (Fig. 6a).
Confocal imaging of LLT1-EYFP-transfected epithelial cells
interacting with transiently transfected T cells expressing CD161-
mCherry was performed. A low proportion of T cells were trans-
fected, allowing comparison between CD161 (red) and CD161
lymphocytes (seen as round cells in Fig. 6b). When CD161 lym-
phocytes (seen as red cells in Fig. 6b) came into contact with the
LLT1-expressing bronchial epithelial cells (green) (Fig. 6b), both
molecules accumulated at the site of contact. There was no accu-
mulation of LLT1 at sites of contact with the majority untrans-
fected T cells (visible in the transmission image, but not in the red
or green channels) (Fig. 6b). At the site of interaction, the distri-
bution of LLT1-EYFP and CD161-mCherry clearly overlapped,
demonstrating coclustering of these molecules and the require-
ment for lymphocyte CD161 for LLT1 clustering (Fig. 6b; shown
at highmagnification in Fig. 6c). Of 40 synapses observed in trans-
fected T cells, 39 (97.5%) showed prominent coclustering of LLT1
and CD161. Of 159 untransfected Jurkat cells, none (0%) led to
prominent clustering of LLT1 at the T cell-epithelial cell interface.
The large, synapse-wide accumulations of CD161/LLT1 were ini-
tially formed as small dynamic clusters at the T cell-bronchial
epithelial cell interface, which coalesced (not shown). These struc-
tures were further characterized by receptorless “voids,” which
perforated otherwise homogeneous accumulations of LLT1/
CD161 (Fig. 6c). This suggests that upon upregulation of LLT1 on
epithelial cells, as is seen following respiratory-virus infection, the
ligand can interact with CD161 and accumulate at the immune
synapse formed with CD161-expressing lymphocytes.
DISCUSSION
Understanding the mechanisms by which respiratory-virus infec-
tion promotes the activation of lymphocytes in the lung is a key
goal. The importance of the epithelium as a regulator of leukocyte
responses in the lung is becoming increasingly apparent. Here, we
show that the CD161 ligand LLT1 is expressed on bronchial epi-
thelial cells in response to RSV infection and TLR ligation and in
response to the proinflammatory cytokines type I interferons, IL-
1, and TNF-	. We demonstrate that LLT1 expressed in the re-
spiratory epithelium traffics to the epithelial surface and interacts
at the immune synapse with CD161 lymphocytes. The CD161
receptor is expressed on proinflammatory lymphocytes at muco-
sal sites, including the lungs, and thus, expression of LLT1 on
respiratory epithelial cells following viral infection links innate
and adaptive immunity and could be an important regulator of
lymphocyte activation in the lung.
LLT1 transcript expression in response to TLR3 recognition of
poly(I·C) peaked at 4 to 8 h. This is remarkably rapid compared to
previously published observations of other cell types. LLT1 ex-
pression on T and B lymphocytes and dendritic cells was reported
after 24 to 72 h of stimulation (8, 10). In whole-blood peripheral
bloodmononuclear cells (PBMC), ligands for TLR3, TLR4, TLR7,
TLR8, or TLR9 were able to induce LLT1 expression (8). In den-
dritic cells, ligands for TLR3, TLR4, TLR 7/8, and TLR9 induce
LLT1, and in B cells, TLR7/8 and TLR9 induce expression (8, 10).
This is in contrast to our findings of a lack of induction by the
TLR4 ligand LPS, the TLR9 ligand CpG, or TLR7/8 ligands in the
epithelium. We did find expression induced by FSL-1, a synthetic
mycobacterium-derivedmycoprotein that stimulates TLR2/6. In-
terestingly, mycobacteria can also increase expression of the MR1
FIG 5 LLT1 protein expression in bronchial epithelial cells. BEAS-2B cells
were stimulatedwith 10,000U/ml IFN-, 10 ng/ml IL-1, 10 ng/ml TNF-	, or
10 g/ml poly(I·C) for 16 h, and immunohistochemistry was carried out for
LLT1 protein expression. LLT1 expressionwas visualized usingDAB substrate,
which forms a brown precipitate. Scale bar 50 m.
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molecule, which presents antigen to MAIT cells (28, 29). MAIT
cells are abundant, unconventional, antimicrobial CD8CD161
T cells found at mucosal surfaces that may play roles in respirato-
ry-bacterial infection (30–32). Therefore, LLT1 is induced in a
number of cell types in response to microbial stimuli and thus
provides a link between pattern recognition and lymphocyte acti-
vation.
Detection of viral infection by the host leads to the production
of type I interferons. We show that IFN- and IFN-	 are potent
inducers of LLT1 expression in epithelial cells. In cocultures of
RSV-infected and uninfected cells, both infected and uninfected
cells upregulated LLT1 expression, indicating that soluble media-
tors could induce LLT1 expression. Interestingly, staining ap-
peared brighter in uninfected cells. This could be because of spe-
cific or nonspecific inhibition of LLT1 synthesis in infected cells.
Alternatively, it is consistent with inhibition ofmediator signaling
in infected cells, particularly RSV nonstructural protein (NS1 and
NS2) inhibition of type I interferon signaling. We also observed
induction of expression by the proinflammatory cytokines TNF-	
and IL-1. It will be interesting to find out whether these cyto-
kines can induce LLT1 expression on other cell types and whether
they in fact indirectly mediate the effects of other TLR ligands or
virus infections previously reported by others.
From our data, it can be concluded that cell surface LLT1 in-
teracts to form an immune synapse with lymphocytes expressing
the receptor CD161. CD161 has been shown to be involved in a
number of aspects of the lymphocyte response. CD161 can inhibit
cytotoxicity and IFN- secretion of NK cells (7, 25). In T cells, the
role of CD161 continues to be debatable. Some authors report no
effects or inhibitory effects on T cells (8); however, others demon-
strate costimulation of conventional and CD1d-restricted T cells
and thymocytes following CD161 ligation, which promotes their
activation, proliferation, and cytokine secretion (5–7, 9, 10).
CD161 lymphocytes are important proinflammatory lym-
phocytes in respiratory disease. Taken together, our data demon-
strate that LLT1 is expressed on the epithelial surface in response
to TLR ligands and by proinflammatory cytokines that would be
released during respiratory-virus infection. This suggests a mech-
anism by which activation of CD161 lymphocytes may be regu-
lated by the epithelium during infection. As a consequence, NK
FIG 6 Epithelial LLT1 accumulates at the immune synapse with CD161 T lymphocytes. (a) Flow cytometric analysis of CD161 surface expression as detected
using a CD161-APC antibodywith or without transfectionwith a CD161-EYFP construct. (b) BEAS-2B cells were transfected (Trans) to express LLT1-EYFP and
were imaged by confocal microscopy interacting with T lymphocytes transfected to express CD161-mCherry. The low-magnification images show many T
lymphocytes (small round cells), two of which are transfected with CD161 (red), in contact with BEAS-2B cells transfected with LLT1-EYFP (green). (c)
High-magnification image of a single synapse formed with a CD161 lymphocyte showing colocalization of CD161 and LLT1. The arrows indicate a void in the
synapse lacking both receptor and ligand. Scale bars 10 m.
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cell activation may be reduced, which may protect the epithelial
cells from NK-mediated lysis. Conversely, activation of proin-
flammatory CD161 lymphocytes, particularly Th17 and Tc17
subsets, may be promoted. LLT1 expression thus provides a link
between respiratory-virus infection and activation of proinflam-
matory lymphocytes. As such, LLT1 may represent a novel target
for regulation of excessive respiratory inflammation caused by
acute infection, such as in RSV bronchiolitis, and in viral exacer-
bations of chronic diseases, such as chronic obstructive pulmo-
nary disease (COPD) and asthma.
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